Le Lézard
Classified in: Health
Subject: PLW

Circadiance Granted US and International Patents for SleepWeaver® Soft Cloth CPAP Masks


PITTSBURGH, Aug. 7, 2018 /PRNewswire-PRWeb/ -- Circadiance, a pioneer in respiratory therapy specializing in positive airway pressure, non-invasive ventilation and remote patient monitoring, announced today that it has received two additional patents for its SleepWeaver line of Soft Cloth CPAP Masks. The United States Patent and Trademark Office (USPTO) has granted a patent titled "Full Face Cloth Respiratory Mask" to Circadiance covering certain features of the SleepWeaver Anew Soft Cloth Full Face CPAP Mask under the patent number of 9,981,104. The United Kingdom Patent Office (UKIPO) has granted a patent titled "Improved Respiratory Mask with Disposable Cloth Body" covering certain features of the SleepWeaver Elan Soft Cloth CPAP Mask under the patent number of 2,504,598.

With the addition of these two patents, Circadiance holds 9 US and international patents around its cloth masks technology. "These patents provide further validation of the novelty of our CPAP mask solutions" said David Groll, founder, and CEO of Circadiance. "Circadiance customers report that CPAP masks made of cloth are more comfortable and easier to wear because they are lighter and softer than hard plastic CPAP masks."

The SleepWeaver line are the only cloth masks on the market. SleepWeaver Masks are for use in conjunction with Continuous Positive Airway Pressure (CPAP) or bi-level therapy, which is the most frequent treatment for Obstructive Sleep Apnea. SleepWeaver masks are the lightest and softest masks available to CPAP users. The masks provide enhanced comfort to the user because cloth allows the skin to breathe, without moisture accumulating between the mask and the user's skin. The soft cloth masks are particularly important for those CPAP users who experience skin reactions to hard plastic masks. The unique loose fit provides added comfort and reduces strap marks. All Circadiance masks allow for a variety of sleep positions.

SleepWeaver Anew® was launched in 2013. SleepWeaver Anew is an alternative to hard plastic masks for Full Face CPAP mask users. The mask features a dual interface design that seals around both the nose and the mouth, with only soft cloth touching the skin. SleepWeaver Anew is available in multiple sizes to ensure that users find the perfect fit for their face.

SleepWeaver Elan® was launched in 2012. SleepWeaver Elan is an alternative to hard plastic masks for Nasal CPAP mask users. The mask features a design that seals around the nose, again with only soft cloth touching the skin.SleepWeaver Elan is available in multiple sizes to ensure that users find the perfect fit for their face.

Each of these patent applications were filed prior to the launch of their respective products. It is not unusual for patents to issue years after the initial application filing. "The addition of these patents to our portfolio strengthens our intellectual property position in the global CPAP mask market" continued Groll. The market opportunity for CPAP Masks is large and growing. Available data indicate that the global market for CPAP Masks is approximately USD$2 billion, growing at a compound annual rate of 9.2% through to 2022.

About Circadiance:
Circadiance is a pioneer in respiratory therapy medical devices specializing in positive airway pressure, noninvasive ventilation and apnea monitoring. Our clinically proven, innovative solutions address patients ranging from premature newborns, pediatrics, children to adults. Circadiance's brands include the following:

SleepWeaver® ? Soft Cloth CPAP Masks

Smart Monitor® ? Infant Apnea Monitors

NeoPAP® ? Neonatal CPAP and High Flow Respiratory Support System

For more information about Circadiance, contact customer service at (888)-825-9640. International inquiries should call +1-724-858-2837. You can also visit Circadiance.com.

 

SOURCE Circadiance


These press releases may also interest you

at 07:05
At the ESCMID Global 2024 conference, Bruker is enhancing its innovative diagnostic solutions in microbial identification, antimicrobial susceptibility testing (AST), early sepsis diagnostics, and other infectious disease assays. Simplifying...

at 07:00
Bristol Myers Squibb today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Opdivo® (nivolumab) in combination with cisplatin and gemcitabine for the...

at 07:00
R&D Leader and software architect with more than three decades of experience designing, developing,...

at 07:00
Gordian Biotechnology, an in vivo drug discovery and development...

at 07:00
GeBBS Healthcare Solutions, Inc.(ChrysCapital portfolio company) a leading provider of technology enabled Revenue Cycle Management (RCM) & Risk Adjustment Solutions for Healthcare Providers and Payers, announced the acquisition of CCD Health, a...

at 07:00
Many American children...



News published on and distributed by: